TOFRANIL

Post-LOE

imipramine hydrochloride

Novartis

ANDAORALTABLET

Approved

May 1984

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TOFRANIL (imipramine hydrochloride) by Novartis is clinical pharmacology the mechanism of action of imipramine hydrochloride is not definitely known. Approved for depression, depression. First approved in 1984.

Drug data last refreshed Yesterday

Mechanism of Action

CLINICAL PHARMACOLOGY The mechanism of action of imipramine hydrochloride is not definitely known. However, it does not act primarily by stimulation of the central nervous system. The clinical effect is hypothesized as being due to potentiation of adrenergic synapses by blocking uptake of…

Indications (1)

Depression

Clinical Trials (1)

NCT00946764Phase 1Completed

To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions

Started Jul 2005

48 enrolled

Depression

Worked on TOFRANIL at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.